HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$31.21
Day range
$28.79 - $31.33
Year range
$23.15 - $49.05
Market cap
1.57B USD
Avg Volume
303.83K
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 93.88M | 33.16% |
Operating expense | 96.67M | -0.08% |
Net income | 5.02M | 120.56% |
Net profit margin | 5.35 | 115.44% |
Earnings per share | 0.10 | 116.34% |
EBITDA | -2.76M | 89.16% |
Effective tax rate | 17.44% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 837.03M | 0.51% |
Total assets | 1.03B | 3.42% |
Total liabilities | 649.53M | 2.38% |
Total equity | 378.48M | — |
Shares outstanding | 50.23M | — |
Price to book | 4.14 | — |
Return on assets | -0.89% | — |
Return on capital | -1.13% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 5.02M | 120.56% |
Cash from operations | 435.00K | 109.48% |
Cash from investing | 9.70M | 2,356.28% |
Cash from financing | 2.55M | -99.36% |
Net change in cash | 21.11M | -94.59% |
Free cash flow | -59.40M | -16,674.99% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
493
